# RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

> **NCT00621855** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1878 (actual)

## Conditions studied

- Coronary Disease

## Interventions

- **DRUG:** placebo
- **DRUG:** dabigatran etexilate
- **DRUG:** dabigatran etexilate
- **DRUG:** dabigatran etexilate
- **DRUG:** dabigatran etexilate

## Key facts

- **NCT ID:** NCT00621855
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 1878 (ACTUAL)
- **Last updated:** 2014-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621855, "RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00621855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*